Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | -174.84K | -154.68K | -97.42K | -3.39K |
EBITDA | -21.24M | -20.59M | -15.79M | -14.42M | -12.27M | -5.90M |
Net Income | -19.88M | -20.78B | -15.96M | -14.09M | -12.30M | -5.91M |
Balance Sheet | ||||||
Total Assets | 21.10M | 25.57M | 43.65M | 58.84M | 73.95M | 20.36M |
Cash, Cash Equivalents and Short-Term Investments | 19.72M | 24.01M | 41.30M | 55.20M | 70.73M | 19.23M |
Total Debt | 194.93K | 243.66K | 234.47K | 52.89K | 204.95K | 108.50K |
Total Liabilities | 4.32M | 4.38M | 2.74M | 2.80M | 2.38M | 660.84K |
Stockholders Equity | 16.78M | 21.19B | 40.91M | 56.04M | 71.57M | 19.70M |
Cash Flow | ||||||
Free Cash Flow | -19.13M | -17.83M | -14.37M | -12.80M | -10.61M | -5.67M |
Operating Cash Flow | -19.12M | -17.81M | -14.35M | -12.77M | -10.59M | -5.65M |
Investing Cash Flow | 7.16M | 3.37M | -930.21K | 179.27K | -19.53M | -16.14K |
Financing Cash Flow | 66.66M | 66.71K | -500.00K | ― | 63.42M | 23.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
45 Neutral | $33.97M | ― | -75.66% | ― | ― | -31.16% | |
39 Underperform | $45.30M | ― | -83.71% | ― | ― | ― | |
39 Underperform | $47.12M | ― | -82.81% | ― | -92.95% | -50.02% | |
38 Underperform | $97.68M | ― | 0.00% | ― | ― | ― | |
36 Underperform | $151.94M | ― | -130.27% | ― | ― | 43.64% | |
34 Underperform | $31.68M | ― | -49.32% | ― | ― | 38.98% |
On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.